1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Pfizer’s RSV Vaccine Shows Efficacy In Older Adults, Setting Up Showdown With GSK

 
• By Joseph Haas

Pfizer’s bivalent vaccine candidate showed efficacy in RSV patients with multiple respiratory infection symptoms and may offer protection against the A and B strains of the virus.

RSV illustration
Pfizer is readying a BLA filing for its RSV vaccine candidate • Source: Shutterstock

Pfizer Inc. pulled into a virtual tie with GSK plc in the five-company race to bring to market a new vaccine to prevent respiratory syncytial virus (RSV) infections, announcing data on 25 August that show its bivalent candidate RSVpreF demonstrated efficacy in adults 60 and older with two or more symptoms of related lower respiratory tract infections and in patients with three or more symptoms as well.

GSK said on 10 June that its adjuvanted protein vaccine candidate, GSK3844766A, showed what it called “exceptional” results in healthy volunteers aged 60 and older, but unlike Pfizer, did not release numerical data from its Phase III study. (Also see "GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial" - Scrip, 10 June, 2022.) Pfizer’s top-line data readout from its Phase III RENOIR trial showed vaccine efficacy in 66

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D